Serum levels of free, acyl, and total carnitine were determined in 32 patients with seizures, before and after 3, 6, and 12 months of treatment with valproic acid (17 patients), carbamazepine (10 patients), or phenobarbital (5 patients). In all three treated groups, both free and total carnitine levels showed a significant decline with respect to pretreatment levels. This decline was most marked and most consistent in patients treated with valproic acid. In 35% of the patients in this group, carnitine deficiency (ie, total camitine < 30 μmol/L) was observed by month 12. In none of the three groups were serum carnitine levels significantly correlated with the serum concentration of the drug. These findings suggest a need to monitor serum carnitine levels in children treated with any of these drugs. (J Child Neurol 1998;13:546-549).
Get full access to this article
View all access options for this article.
References
1.
Ohtani Y., Endo F., Matsuda I.: Carnitine deficiency and hyperammonemia associated with valproic acid therapy . J Pediatr1982; 101:782-785.
2.
Laub MC, Paetzke-Brunner I., Jaeger G.: Serum carnitine during valproic acid therapy. Epilepsia1982;27:559-562.
3.
Bates SR, Hug G.: Carnitine reduction and anticonvulsants in children. Ann Neurol1989;26:468-469.
4.
Beghi E., Rizzi A., Codegoni AM, et al: Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia1990;31:346-352.
5.
Opala G., Winter S., Vance C., et al: The effect of valproic acid on plasma carnitine levels. Am J Dis Child1991;145:999-1001.
6.
Thom H., Carter PE, Cole GF, Stevenson KL: Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol1991;33:795-802.
7.
Hug G., McGraw CA, Bates SR, Landrigan EA: Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children . J Pediatr1991;119:799-802.
8.
Rodríguez-Segade S., Alonso de la Peña C., Tutor JC, et al: Carnitine deficiency associated with anticonvulsant therapy. Clin Chim Acta1989;181:175-182.
9.
Castro-Gago M., Novo I., Rodriguez-Segade S.: Effects of valproic acid on the urea cycle and carnitine metabolism. Int Pediatr1990;5:54-57.
10.
Castro-Gago M., Bernabeu FA, Novo I., et al: Efecto de los fármacos anticomiciales sobre el metabolismo renal de la carnitina. Rev Neurol (Barcelona) 1994;22:646-650.
11.
Nishida N., Sugimoto R., Araki A., et al: Carnitine metabolism in valproate-treated rats: The effect of L-carnitine supplementation. Pediatr Res1987 ;22:500-503.
12.
Rozas I., Camiña MF, Paz JM, et al: Effects of acute valproate administration on carnitine metabolism in mouse serum and tissues. Biochem Pharmacol1990;39:181-185.
13.
Camiña F., Rozas I., Castro-Gago M., et al: Alteration of renal carnitine metabolism by anticonvulsant treatment . Neurology1991; 41:1444-1448.
14.
Camiña F., Rozas I., Gómez M., et al: Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues. Br J Pharmacol1991; 103:1179-1183.
15.
Mitchell ME : Carnitine metabolism in human subjects. I. Normal metabolism. Am J Clin Nutr1978;31:293-299.
16.
Castro-Gago M., Camiña F., Rodriguez-Segade S.: Carnitine deficiency caused by valproic acid, letter. J Pediatr1992;120:496.
17.
Coulter DL: Carnitine deficiency in epilepsy: Risk factors and treatment. J Child Neurol1995;10(Suppl):2S32-2S39.
18.
Campos Y., Huertas R., Lorenzo G., et al: Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve1993;16:150-153.
19.
Rodríguez-Segade S., Alonso de la Peña C., Paz JM, Del Río R.: Determination of L-carnitine in serum, and implementation on ABA-100 and CentrifiChen 600. Clin Chem1985;31:754-757.
20.
McGarry JD, Foster DW: An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Res1976 ;17:277-281.
21.
Zelnik N., Fridkis I., Gruener N.: Reduced carnitine and antiepileptic drugs: Cause relationship or co-existence?Acta Paediatr1995;84:93-95.
22.
Riva R., Albani F., Gobbi G., et al: Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia1993;34:184-187.
23.
Schmidt-Sommerfeld E., Werner D., Penn D.: Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr1988;147:356-360.
24.
Pons R., De Vivo DC: Primary and secondary carnitine deficiency syndromes. J Child Neurol1995; 10(Suppl):2S8-2S24.
25.
Komatsu M., Kodoma S., Yokoyama S., et al: Valproate-associated hyperammonemia and DL-carnitine supplement. Kobe J Med Sci1987;33:81-87.
26.
Tein I., DiMauro S., Xie Z-W., De Vivo DC: Valproic acid impairs carnitine uptake in cultured human skin fibroblasts: An in vitro model for the pathogenesis of valproic acid associated carnitine deficiency. Pediatr Res1993;34:281-287.
